We're always working to initiate change for patients
This section includes information and helpful resources so you can stay up to date on the latest UroGen innovations, events, news coverage, and more.
UroGen® profile
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urological and specialty cancers because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGel®, a reverse-thermal sustained-release hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained-release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.
Jelmyto® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade intermediate risk non-muscle invasive bladder cancer, are designed to ablate tumors by nonsurgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
Our leadership
News releases
Dec 6, 2024
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 6, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 35 new
Read storyDec 5, 2024
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
Favorable long-term durability data further supports JELMYTO as a primary treatment for low-grade upper tract urothelial cancer PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 5, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions
Read storyDec 5, 2024
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
UGN-102 demonstrated 82.3% duration of response (DOR) at 12 months in patients who achieved complete response at 3 months 79.6% complete response rate at 3 months in patients treated with UGN-102 Safety profile consistent with prior clinical trials of UGN-102 PRINCETON, N.J. --(BUSINESS WIRE)--Dec.
Read story